Paratek withdraws European MAA for oral and intravenous NUZYRA in skin infections
Paratek announced he company has withdrawn its submission to the EMA of the Marketing Authorization Application for NUZYRAź (omadacycline). NUZYRA is a once-daily oral and IV modernized tetracycline approved by the FDA Oct. 2, 2018 for treatment of adults with CABP and ABSSSI. October 17, 2019